Skip to main content
Clinical Trials/NCT03988699
NCT03988699
Completed
N/A

Novel Tinnitus Implant System for the Treatment of Chronic Severe Tinnitus: An Early Feasibility Study

Matthew L. Carlson, M.D.1 site in 1 country9 target enrollmentAugust 23, 2021
ConditionsTinnitus

Overview

Phase
N/A
Intervention
Not specified
Conditions
Tinnitus
Sponsor
Matthew L. Carlson, M.D.
Enrollment
9
Locations
1
Primary Endpoint
Number of subjects with treatment-related adverse events
Status
Completed
Last Updated
7 months ago

Overview

Brief Summary

Researchers are gathering information on the safety and effectiveness of a novel device called the Tinnitus Implant System for the treatment of tinnitus.

Detailed Description

This study requires one year of participation with at least 21 visits to Mayo Clinic in Rochester MN for device programming and audiometric testing. The device is implanted during an outpatient surgery. Participants may keep the study device after participation is complete.

Registry
clinicaltrials.gov
Start Date
August 23, 2021
End Date
September 10, 2024
Last Updated
7 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Matthew L. Carlson, M.D.
Responsible Party
Sponsor Investigator
Principal Investigator

Matthew L. Carlson, M.D.

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Number of subjects with treatment-related adverse events

Time Frame: One year

Measured by subjects meeting one or more of the following criteria: worsening bone conduction thresholds in any tested frequency (0.25, 0.5, 1, 1.5, 2, 3, or 4 kHz) from baseline by a clinically significant amount (\>10 dB) or worsening in WRS from baseline by a clinically significant amount (\>20%) or worsening in video head impulse test result from baseline or one or more serious AEs

Number of subjects to experience significant improvement from implantation of the device

Time Frame: Baseline, 3 weeks, 5 weeks, 7 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 52 weeks

Measured by subjects meeting at least two of three measurements of tinnitus severity: Tinnitus Handicap Inventory (THI) improvement by greater than 7 points using a 25-item self-assessment questionnaire with possible answers of Yes (4 points), Sometimes (2 points), and No (0 points) or Tinnitus Functional Index (TFI) improvement by greater than 13 points using a 25-item self-report questionnaire on a scale of 0 to 10 with a maximum possible score of 250 or Tinnitus visual analog scale improvement by greater than 15 points using a self-reported scale consisting of a 10 cm line with verbal descriptors (word anchors) at each end to express the extremes of the symptom; 0 mm designates no pain and 100 mm designates the greatest imaginable severity of pain.

Study Sites (1)

Loading locations...

Similar Trials